TITLE

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort

AUTHOR(S)
Schnitzler, F.; Fidder, H.; Ferrante, M.; Noman, M.; Arijs, I.; Van Assche, G.; Hoffman, I.; Van Steen, K.; Vermeire, S.; Rutgeerts, P.
PUB. DATE
April 2009
SOURCE
Gut;Apr2009, Vol. 58 Issue 4, p492
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.
ACCESSION #
45646932

 

Related Articles

  • Infliximab.  // Reactions Weekly;10/16/2010, Issue 1323, p25 

    The article describes the cases of two women who developed Lewis-Summer syndrome (LSS) while receiving treatment with infliximab for Crohn's disease (CD).

  • Infliximab.  // Reactions Weekly;5/15/2010, Issue 1301, p29 

    The article describes the case of two men who developed fulminant legionellosis after being given infliximab as treatment for Crohn's disease.

  • Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn's Disease Patients Failing Infliximab. Steenholdt, Casper; Brynskov, Jørn; Thomsen, Ole; Munck, Lars; Fallingborg, Jan; Christensen, Lisbet; Pedersen, Gitte; Kjeldsen, Jens; Jacobsen, Bent; Oxholm, Anne; Kjellberg, Jakob; Bendtzen, Klaus; Ainsworth, Mark // Digestive Diseases & Sciences;Sep2015, Vol. 60 Issue 9, p2762 

    Background: In Crohn's disease patients failing infliximab therapy, interventions defined by an algorithm based on infliximab and anti-infliximab antibody measurements have proven more cost-effective than intensifying the infliximab regimen. Aim: This study investigated long-term economic...

  • New Relief for Crohn's Disease. Harrar, Sari; Metcalf, Eric // Prevention;Mar2002, Vol. 54 Issue 3, p155 

    Reports that the steroid drug budesonide is effective in treating Crohn's disease flare-ups and has fewer side effects than prednisone, the conventional therapy.

  • Controversies in the treatment of Crohn's disease: The case for an accelerated step-up treatment approach. Shergill, Amandeep K.; Terdiman, Jonathan P.; Wexner, Steven D.; Duchmann, Rainer J. // World Journal of Gastroenterology;5/7/2008, Vol. 14 Issue 17, p2670 

    The ideal treatment strategy for Crohn's disease (CD) remains uncertain, as does the optimal endpoint of therapy. Top-down versus step-up describes two different approaches: early use of immunomodulators and biological agents in the former versus initial treatment with steroids in the latter,...

  • Healing of Crohn's disease enterovesical fistula, with the use of infliximab: a case report. Steinwurz, Flavio // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS238 

    An abstract of the article concerning infliximab treatment of Crohn's disease is presented.

  • Infliximab treatment for Crohn's disease treated with elemental diet: the Tokyo experience. Tanaka, Torao; Takazoe, Masakazu; Morita, Eijirou; Terabe, Fumitaka // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS252 

    An abstract of the article concerning infliximab treatment with elemental diet for Crohn's disease is presented.

  • Treatment of cutaneous Crohn's disease with infliximab. Mitchell, Sara H; Varano, Vincent J; Komar, Michael J // American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS250 

    An abstract of the article concerning infliximab treatment of cutaneous crohn's disease is presented.

  • Economic benefit of algorithm-based therapy after IFX failure.  // PharmacoEconomics & Outcomes News;Feb2015, Vol. 722 Issue 1, p14 

    The article reports on the Danish research indicating the economic advantage of individualised algorithm-based therapy after the failure of infliximab (IFX) in treating patients suffering from Crohn's disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics